PSYCH OpenIR  > 认知与发展心理学研究室
Amiloride does not protect retinal nerve fibre layer thickness in optic neuritis in a phase 2 randomised controlled trial
McKee, Justin B.1,2; Cottriall, Charles L.3; Elston, John3; Epps, Simon4; Evangelou, Nikos5; Gerry, Stephen6; Kennard, Christopher7; Kong, Yazhuo8,9; Koelewyn, Abigail1; Kueker, Wilhelm10; Leite, Maria Isabel1; Palace, Jacqueline1; Craner, Matthew1
First AuthorMcKee, Justin B.
2019-02-01
Source PublicationMULTIPLE SCLEROSIS JOURNAL
Correspondent Emailm craner(matthew.craner@ndcn.ox.ac.uk)
ISSN1352-4585
Subtypearticle
Volume25Issue:2Pages:246-255
Abstract

Background: Recent basic and clinical evidence suggests amiloride may be neuroprotective in multiple sclerosis (MS) through the blockade of the acid sensing ion channel (ASIC). Objective: To examine the neuroprotective efficacy of amiloride in acute optic neuritis (ON). Methods: A total of 48 patients were recruited to a phase 2, double blind, single site, randomised controlled trial. Scanning laser polarimetry (GDx) at 6 months was the primary outcome measure and optical coherence tomography (OCT) and visual and electrophysiological measures were secondary outcome measures. Participants aged 18-55 years, <= 28 days of onset of first episode unilateral ON, were randomised to amiloride (10 mg daily for 5 months) or placebo (, NCT 01802489). Results: Intention-to-treat (ITT) cohort consisted of 43 patients; 23 placebo and 20 amiloride. No significant drug-related adverse events occurred. No significant differences were found in GDx (p = 0.840). Visual evoked potentials (VEP) were significantly prolonged in the amiloride group compared to placebo (p = 0.004). All other secondary outcome measures showed no significant difference. Baseline analysis of OCT data demonstrated a significant pre-randomisation thinning of ganglion cell layer. Conclusion: Amiloride has not demonstrated any neuroprotective benefit within this trial paradigm, but future neuroprotective trials in ON should target the window of opportunity to maximise potential neuroprotective benefit.

KeywordClinical trial outcome measurement multiple sclerosis axonal loss
DOI10.1177/1352458517742979
Indexed BySCI
Language英语
Funding ProjectMultiple Sclerosis Society in the UK[952/11]
WOS Research AreaNeurosciences & Neurology
WOS SubjectClinical Neurology ; Neurosciences
WOS IDWOS:000457648700012
PublisherSAGE PUBLICATIONS LTD
WOS KeywordMULTIPLE-SCLEROSIS ; NEUROPROTECTION ; BRAIN ; MECHANISMS ; INJURY ; RISK
Citation statistics
Cited Times:3[WOS]   [WOS Record]     [Related Records in WOS]
Document Type期刊论文
Identifierhttp://ir.psych.ac.cn/handle/311026/28314
Collection认知与发展心理学研究室
Corresponding AuthorCraner, Matthew
Affiliation1.Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Neurosci, Div Clin Neurol, Oxford, England
2.NHS Lothian, Princess Alexandra Eye Pavil, Edinburgh, Midlothian, Scotland
3.Oxford Univ Hosp NHS Fdn Trust, Oxford Eye Hosp, Oxford, England
4.Univ Bristol, Sch Clin Sci, Ophthalmol, Bristol, Avon, England
5.Univ Nottingham, Fac Med & Hlth Sci, Nottingham, England
6.Univ Oxford, Ctr Stat Med, Oxford, England
7.Univ Oxford, John Radcliffe Hosp, Med Sci Div, Oxford, England
8.Univ Oxford, Nuffield Dept Clin Neurosci, Oxford Ctr Funct Magnet Resonance Imaging Brain F, Oxford, England
9.Chinese Acad Sci, Inst Psychol, Beijing, Peoples R China
10.Oxford Univ Hosp NHS Fdn Trust, John Radcliffe Hosp, Dept Neuroradiol, Oxford, England
Recommended Citation
GB/T 7714
McKee, Justin B.,Cottriall, Charles L.,Elston, John,et al. Amiloride does not protect retinal nerve fibre layer thickness in optic neuritis in a phase 2 randomised controlled trial[J]. MULTIPLE SCLEROSIS JOURNAL,2019,25(2):246-255.
APA McKee, Justin B..,Cottriall, Charles L..,Elston, John.,Epps, Simon.,Evangelou, Nikos.,...&Craner, Matthew.(2019).Amiloride does not protect retinal nerve fibre layer thickness in optic neuritis in a phase 2 randomised controlled trial.MULTIPLE SCLEROSIS JOURNAL,25(2),246-255.
MLA McKee, Justin B.,et al."Amiloride does not protect retinal nerve fibre layer thickness in optic neuritis in a phase 2 randomised controlled trial".MULTIPLE SCLEROSIS JOURNAL 25.2(2019):246-255.
Files in This Item:
File Name/Size DocType Version Access License
Amiloride does not p(1120KB)期刊论文出版稿限制开放CC BY-NC-SAView Application Full Text
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[McKee, Justin B.]'s Articles
[Cottriall, Charles L.]'s Articles
[Elston, John]'s Articles
Baidu academic
Similar articles in Baidu academic
[McKee, Justin B.]'s Articles
[Cottriall, Charles L.]'s Articles
[Elston, John]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[McKee, Justin B.]'s Articles
[Cottriall, Charles L.]'s Articles
[Elston, John]'s Articles
Terms of Use
No data!
Social Bookmark/Share
File name: Amiloride does not protect retinal nerve fibre layer thickness in optic neuritis in a phase 2 randomised controlled trial.pdf
Format: Adobe PDF
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.